• Recruiting

NCT04025216: Phase 1: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Updated: May 26

NCT04025216: Phase 1: A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

CART-TnMUC1

Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).



Sponsor

Tmunity Therapeutics


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04025216


Official Title: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma


First Posted : July 18, 2019


Click here to see details on ClinicalTrials.gov

 

Biological: CART-TnMUC1

Drug: Cyclophosphamide

Drug: Fludarabine

 

Anti-TnMUC1-CAR-expressing Autologous T-lymphocytes


Autologous Tn-MUC1-specific CAR T-lymphocytes (Code C165433)

Anti-TnMUC1-CAR-expressing Autologous T-lymphocytes

Autologous Anti-TnMUC1-CAR-expressing T-lymphocytes

Autologous CART-TnMUC1 Cells

Autologous Tn-MUC1-specific CAR T Cells

Autologous Tn-MUC1-specific CAR T-lymphocytes

Autologous TnMUC1-targeted Genetically-Modified CAR T Cells

 

Locations

United States, Arizona

United States, California

United States, Florida

United States, Illinois

United States, Missouri

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Washington







Posts Archive